Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › apatinib

apatinib

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of apatinib

8 trials tracked of apatinib: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 693 citations.

8Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3 Phase 2 5
  1. Phase 3 A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC Completed · 693 cited
  2. Phase 3 Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP) Completed · 256 cited
  3. Phase 3 Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Completed
  4. Phase 2 Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006) Completed
  5. Phase 2 SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy Completed
  6. Phase 2 A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC Completed
Show 2 more trials
  1. Phase 2 A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) Completed
  2. Phase 2 A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Camrelizumab and apatinib show higher response rates and survival in treatment-naive patients with ESCC
ENT (Otolaryngology) Meta-analysis
Camrelizumab and apatinib show higher response rates and survival in treatment-naive patients with ESCC Treatment Naive Patients Show Better Survival with Camrelizumab and Apatinib
This meta-analysis evaluates the efficacy of camrelizumab plus apatinib for advanced or metastatic esophageal squamous cell carcinoma. The a…
Patients with advanced esophageal cancer who have not had prior treatment may see better survival rates when using a combination of camreliz…
Jul 25, 2026
Case report describes multimodal treatment and single-cell sequencing in NF1 patient with Malignant Triton Tumor
Oncology
Case report describes multimodal treatment and single-cell sequencing in NF1 patient with Malignant Triton Tumor What happens when a rare cancer returns? One young woman's story offers a clue
A case report describes a 23-year-old woman with neurofibromatosis type 1 and Malignant Triton Tumor.
A 23-year-old woman with a rare chest tumor found disease stabilization after surgery failed, using a mix of chemotherapy, targeted therapy,…
Frontiers Apr 1, 2026